CDK4 and Myalgia: In Phase III trials exploring CDK4/6 inhibitors in the metastatic setting, myalgia rate was 4.8–11.9% in patients receiving CDK4/6 inhibitors and AIs [9,10,11,24,53,54] (Table 2).